Biotech | March 06, 2022
Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The total cost of the project is estimated at Rs 30 crore
The company plans to expand their capacity to meet the needs of pharma and biotech industries
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Subscribe To Our Newsletter & Stay Updated
